Thrivent Financial for Lutherans Acquires 79,636 Shares of Caribou Biosciences, Inc. (NASDAQ:CRBU)

Thrivent Financial for Lutherans increased its holdings in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) by 74.4% in the fourth quarter, Holdings Channel.com reports. The fund owned 186,621 shares of the company’s stock after buying an additional 79,636 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Caribou Biosciences were worth $297,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the business. Erste Asset Management GmbH bought a new stake in shares of Caribou Biosciences during the third quarter worth $28,000. US Bancorp DE increased its stake in Caribou Biosciences by 3,524.2% in the 4th quarter. US Bancorp DE now owns 27,218 shares of the company’s stock worth $43,000 after buying an additional 26,467 shares during the period. Intech Investment Management LLC bought a new stake in Caribou Biosciences during the 3rd quarter valued at about $43,000. Thrive Wealth Management LLC bought a new stake in Caribou Biosciences during the 4th quarter valued at about $51,000. Finally, Barclays PLC boosted its position in Caribou Biosciences by 122.4% in the 3rd quarter. Barclays PLC now owns 129,839 shares of the company’s stock valued at $255,000 after buying an additional 71,463 shares during the period. Hedge funds and other institutional investors own 77.51% of the company’s stock.

Caribou Biosciences Stock Down 2.2 %

Shares of CRBU stock opened at $0.77 on Friday. The firm has a market cap of $71.38 million, a price-to-earnings ratio of -0.47 and a beta of 2.34. Caribou Biosciences, Inc. has a 52-week low of $0.70 and a 52-week high of $4.67. The company’s 50 day moving average is $1.17 and its 200 day moving average is $1.67.

Caribou Biosciences (NASDAQ:CRBU) last announced its quarterly earnings results on Monday, March 10th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.01. The business had revenue of $2.08 million for the quarter, compared to the consensus estimate of $2.11 million. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. Analysts anticipate that Caribou Biosciences, Inc. will post -1.64 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CRBU has been the topic of a number of research reports. HC Wainwright reaffirmed a “buy” rating and set a $9.00 target price on shares of Caribou Biosciences in a research report on Wednesday, March 19th. Bank of America reduced their price objective on Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Five analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of “Buy” and an average price target of $10.33.

Caribou Biosciences Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.